Vico Therapeutics logo
Startup

Vico Therapeutics

See Vico Therapeutics's full profile

BOOK A DEMO
Headquarters

Netherlands

Founded Year

2019

Total Funding

$31.0M

Employees

11 - 50

Status

Active


About Vico Therapeutics

Vico Therapeutics focuses on the development of RNA modulating therapies for rare neurological disorders, with initial focus on SCA – Spinocerebellar ataxia, HD – Huntington’s disease and RETT syndrome.

Headquarters

Netherlands


General Information on Vico Therapeutics

Brand name Vico Therapeutics
Company name Vico Therapeutics B.V.
Website https://vicotx.com/
Founded year 2019
Employees 11 - 50
Contact [email protected]
+31712036800

Find startup solutions in your specific business context

The INNOSPOT Startup Discovery platform helps you to find the right startup solutions by leveraging the world's most powerful Startup Search Engine analyzing millions of data points.
BOOK A DEMO

Recent News and Activity about Vico Therapeutics

BioPharm International 30.07.2021
FDA Grants Orphan Drug Designation to VICO Therapeutics for Huntington’s Disease Drug

HD is a rare degenerative brain disease that results in motor disorders, impaired cognition, dementia, and various psychiatric manifestations. It is caused by a mutation to the CAG-trinucleotide repeat in the coding region of exon 1 of the HTT gene, resulting in a mutant huntingtin protein with an elongated polyglutamine (polyQ) stretch at its N-terminus. This grants a toxic gain-of-function to mutant protein forms, which results in widespread ...

Vico Therapeutics news
PharmiWeb.com 30.07.2021
US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659, an Investigational Therapy for Huntington Disease

Leiden, The Netherlands, 29 July 2021 VICO Therapeutics a Leiden Bio Science Park, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the Office of Orphan Products Development (OOPD) of the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for VO659, VICO's investigational antisense oligonucleotide (AON) therapy, for the ...

Vico Therapeutics news
M2 29.07.2021
VICO Therapeutics receives orphan-drug designation from FDA for VO659

Huntington's disease (HD) is a rare inherited...